Study to Compare Blood Levels of Ceftriaxone Given by Suppository or Injection.

Healthy Clinical Trial

— CefREC  

Official title:

A Randomised Crossover Study of the Pharmacokinetics, Safety and Tolerability of Two Rectal Formulations of Ceftriaxone Compared to Parenteral Ceftriaxone, in Healthy Thai Adults.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03895567
• Other study ID #: BAC18003
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: June 2024
• Est. completion date: April 2025

Study information

• Verified date: July 2023
• Source: University of Oxford
• Contact: Elizabeth A Ashley, MD
• Phone: +95(0)1544537
• Email: liz[@]tropmedres.ac
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase 1, three-way cross-over, randomised, open label comparison of intravenous versus two rectal dosage forms of ceftriaxone in 37 healthy Thai adults.

The following regimens will be evaluated in random order in all participants:

A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) B. Ceftriaxone rectal dosage form test formulation 1-hard-shell gelatin capsule (1 x 500mg) C. Ceftriaxone rectal dosage form test formulation 2-rectodispersible mannitol-based tablet (1 x 500mg)

Possible schedules: ABC, ACB, BAC, BCA, CAB, CBA. Each recipient will receive a single treatment dose of each of the three formulations in an order predetermined by a computer generated randomisation list. This will be a constrained randomization which ensures approximately balanced proportions for all six schedules (either 6 or 7 participants per schedule). There will be 7-28 days washout period between doses. The last follow up visit is 28 (+ 2) days after final dose. Participants lost to follow-up or unevaluable for any reason before completion of pharmacokinetic sampling after the final dose will be replaced at the discretion of the investigators with another participant of the same population, if either sample size or completeness of dataset is compromised.

This study is funded by the Medical Research Council. The grant reference number is MR/W021560/1

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 37
• Est. completion date: April 2025
• Est. primary completion date: April 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 46 Years

Eligibility

Inclusion Criteria:

• Healthy male or non-pregnant female, aged 18 to 46 years (inclusive)

• Willing and able to give informed consent to participate in the trial

• Able, in the investigators opinion, and willing to comply with the study requirements and followup.

Exclusion Criteria:

• Female participant who is pregnant, lactating or planning pregnancy during the course of the study.

• Presence of any condition which in the judgment of the investigator would affect the absorption of the rectal formulation e.g. previous surgery, haemorrhoids, inflammatory bowel disease

• Irritable bowel syndrome (IBS) or diarrhoea in the 24 hours prior to study drug administration

• Presence of any condition which in the judgment of the investigator would place the participant at undue risk or interfere with the results of the study (e.g. serious underlying cardiac, renal, hepatic or neurological disease; severe malnutrition; congenital defects or febrile condition).

• Seropositive for HIV at screening

• Hepatitis B surface antigen (HBsAg) detected in serum at screening.

• Seropositive for hepatitis C virus (antibodies to HCV) at screening

• Participation in a clinical trial and/or has received a drug or a new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of study medication and throughout the study period.

• Any medical condition that in the judgment of the investigator would make the administration of the study treatments unsafe.

• Use of medications known to have a potentially clinically significant interaction with ceftriaxone or with sodium chenodeoxycholate (Na-CDC) in the 28 days prior to the first dose and throughout the study period. This includes aluminium-containing antacids, colestipol, phenobarbital and the combined oral contraceptive pill.

• Known 27-hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis)

• History of anaphylaxis and /or hypotension, laryngeal oedema, wheezing, angioedema or urticarial rash following treatment with ceftriaxone, another cephalosporin or any beta lactam (e.g. penicillin).

• History of any other clinically significant reaction to ceftriaxone, another cephalosporin or beta lactam e.g. drug induced nephritis, hepatitis, erythema multiforme that, in the opinion of the investigator, contraindicates participation in the study.

• Serious chronic illness.

• Abnormal baseline laboratory screening test as defined below:

• AST > 2 x upper normal limit

• ALT > 2 x upper normal limit

• Anaemia (Hb < 11 g/dL for female and Hb < 12 g/dL for male),

• Platelets < 150,000

• Total bilirubin > 2 x upper normal limit

• Hepatomegaly, right upper quadrant abdominal pain or tenderness.

• Body Mass Index> 35

• History of alcohol or substance abuse or dependence during the 6 months before study participation: History of regular alcohol consumption averaging >7 drinks/week for women or >14 drinks/week for men. One drink is equivalent to 12 g alcohol = 5 oz (150 mL) of wine or 12 oz (360 mL) of beer or 1.5 oz (45 mL) of 80 proof distilled spirits.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)
Parenteral ceftriaxone Intravenous injection of 500mg of ceftriaxone sodium (Rocephin®; Roche).
• B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)
Rectal ceftriaxone formulations Formulation 1 ceftriaxone 500mg + Na-CDC 125mg hard-shell gelatin capsule
• C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)
Rectal ceftriaxone formulations Formulation 2 ceftriaxone 500mg + Na-CDC 125mg rectodispersible mannitol-based tablet

Locations

Country	Name	City	State
Thailand	Faculty of Tropical Medicine, Mahidol University	Bangkok

Sponsors (2)

Lead Sponsor	Collaborator
University of Oxford	Biopharma (Orofino Pharmaceuticals Group)

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bioavailablity of rectal formulation		Approximately 9 months
Secondary	Description of Exposure (AUC0-8)		Approximately 9 months
Secondary	Description of Peak concentration (Cmax)		Approximately 100 days
Secondary	Description of Absorption rate (Tmax)		Approximately 9 months
Secondary	Time above a plasma concentration of 1µg/mL (this concentration is above the MIC90 for major neonatal pathogens and is the lower limit of detection of the assay)		Approximately 9 months
Secondary	Occurrence of serious adverse events (SAEs) from the date of the first dose to 28 days after the final dose, according to the MedDRA classification.		Approximately 9 months
Secondary	Occurrence of all adverse events from the date of the first dose to 28 days after the final dose, according to the MedDRA classification.		Approximately 9 months